Abstract: The death-associated protein kinase 2 (DAPK2) belongs to a family of Ca 2؉ /calmodulinregulated serine/threonine kinases involved in apoptosis. During investigation of candidate genes operative in granulopoiesis, we identified DAPK2 as highly expressed. Subsequent investigations demonstrated particularly high DAPK2 expression in normal granulocytes compared with monocytes/ macrophages and CD34 ؉ progenitor cells. Moreover, significantly increased DAPK2 mRNA levels were seen when cord blood CD34 ؉ cells were induced to differentiate toward neutrophils in tissue culture. In addition, all-trans retinoic acid (ATRA)-induced neutrophil differentiation of two leukemic cell lines, NB4 and U937, revealed significantly higher DAPK2 mRNA expression paralleled by protein induction. In contrast, during differentiation of CD34
INTRODUCTION
During hematopoietic differentiation, pluripotent, hematopoietic stem cells differentiate into functionally and morphologically distinct end-stage cells. Differentiation is tightly linked to cell cycle regulation and apoptosis, and it is coordinated through the regulation of different key genes and gene programs. Deregulation of hematopoietic differentiation can result in the development of leukemia. For example, in acute myeloid leukemia (AML), malignant cells typically show maturation arrest at various stages of myeloid differentiation [1] .
To identify new candidate genes operative in the regulation of myeloid differentiation, we have recently used microarray gene expression analysis of NB4 cells differentiated in tissue culture toward granulocytes in the presence of all-trans retinoic acid (ATRA). A gene, death-associated protein kinase 2 (DAPK2), also known as death-associated protein kinase-related protein 1 (DRP-1), emerged as being up-regulated during NB4 cell differentiation.
DAPK2 belongs to the family of DAPKs, is a Ca 2ϩ /calmodulin (CaM)-regulated serine/threonine kinase, and functions as a positive mediator of programmed cell death when overexpressed in several cancer cell lines [2, 3] . To date, four other members of the DAPK family have been identified: DAPK1 [4, 5] , DAP-like kinase/zipper-interacting protein kinase [6, 7] , DAPK-related apoptosis-inducing protein 1 and 2 (DRAK1 and DRAK2) [8] . It is interesting that DAPK1, which displays strong kinase homology to DAPK2, has been shown to be epigenetically silenced in several hematological disorders [9, 10] , including AML [11] , acute lymphoblastic leukemia [12, 13] , myelodysplastic syndromes [14] , lymphomas [15, 16] , and myeloma [17] .
Moreover, there is evidence that kinases, such as members of the serine/threonine protein kinase families protein kinase C (PKC) and MAPKs, are implicated in the process of normal and malignant hematopoiesis. PKC␦, for example, was shown to be activated by retinoic acid (RA)-induced differentiation of acute promyelocytic leukemia (APL) cell lines and to form a complex with retinoid acid receptor ␣, allowing the regulation of RAdependent gene transcription [18] . The different MAPK groups play critical roles in the pathogenesis of hematological diseases [19] . Recently, C/EBPε, a member of the C/EBP family involved in neutrophil differentiation [20] , was shown to be phosphorylated by p38 MAPK, resulting in enhanced transcriptional activity of C/EBPε [21] . Conversely, the role of CaM-dependent kinases during neutrophil development and function has only been studied minimally. A report by Lawson et al. [22] described distinct regulation of CaM kinases during ATRA and human recombinant (hr)G-CSF-induced differentiation of murine hematopoietic cell lines. In addition, a recently identified, novel CaM-dependent kinase I-like kinase (CKLiK) has been linked to granulocyte effector functions [23] .
Together, our gene expression profiling findings, showing induction of DAPK2 during neutrophil differentiation, observations of a role for DAPK1 and perhaps for other members of this protein family in leukemogenesis [24] and the important role of kinases during granulocytic maturation, prompted us to investigate DAPK2 expression levels in primary normal and leukemic myeloid cells. To determine correlates of myeloid function, DAPK2 expression was analyzed during in vitro granulo-and monocytic differentiation using cord blood CD34 ϩ progenitor cells and leukemic cell lines. Ectopic and stable expression of DAPK2 as well as expression of small interfering RNA targeting DAPK2 were used to elucidate the possible role of DAPK2 in myeloid differentiation, particularly during terminal granulocyte maturation. Our results implicate a novel role for DAPK2 in the regulation of normal myelopoiesis.
MATERIALS AND METHODS

Cell culture, isolation, and treatment
Six myeloid and seven solid tumor cell lines purchased from the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (Braunschweig, Germany) or American Type Culture Collection (LGC Promochem, Molsheim, France) were maintained in RPMI 1640 or DMEM, supplemented with 10% v/v FCS, 50 U/mL penicillin, and 50 g/mL streptomycin in a 5% CO 2 /95% air-humidified atmosphere at 37°C.
Peripheral blood cells were obtained from buffy coats of normal, healthy donors recruited at the General Clinical Research Center at Green Hospital (La Jolla, CA, USA) or at the Inselspital Bern (Switzerland). The Institutional Review Board of The Scripps Research Institute (La Jolla, CA, USA) and the Inselspital approved protocols and the use of all human samples, respectively. PBMC and granulocytes were isolated using a Ficoll gradient (Lymphoprep™, Axon Lab AG, Switzerland) as described previously [25, 26] . To remove red cells, the cells in the bottom layer were treated with erythrocyte lysis buffer (Qiagen AG, Hombrechtikon, Switzerland) to give a fraction enriched with granulocytes (Ͼ95% purity). The cells in the middle layer were subjected to different isolation procedures. The monocytic population was isolated using the CD14 ϩ isolation system from the MiniMACS separation unit (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) as described by the manufacturer. The purity of each fraction was determined by morphological examination of cytospins stained with May-Grü nwald-Giemsa (Merck, Darmstadt, Germany).
To obtain blood-derived macrophages, 2 ϫ 10 6 /mL monocytes were cultured in the presence of 5000 U/mL hrM-CSF (Sigma-Aldrich, Switzerland) for the indicated times in RPMI-1640 medium supplemented with 10% v/v FCS, 50 units/mL penicillin, and 50 g/mL streptomycin [27] .
Fresh leukemic blast cells from 100 untreated AML patients at diagnosis were classified according to the French-American-British (FAB) classification and cytogenetic analysis. All leukemia samples had blast counts Ͼ90% after separation of mononuclear cells using Ficoll gradient.
Cells from patients with chronic myeloid leukemia in chronic phase (CML-CP) were isolated at diagnosis obtained and treated with erythrocyte lysis buffer (Qiagen AG). Informed consent was obtained from all patients.
In vitro differentiation of leukemic cell lines
For the myeloid differentiation experiments, we used the ATRA-sensitive, human APL cell line NB4 [28] , the ATRA-resistant NB4-R2 subline, and the human acute myelomonocytic leukemia cell line U937. Cells were seeded at a concentration of 1-2 ϫ 10 5 cells/mL and treated with ATRA and PMA as indicated. Cell culture reagents, media, and differentiation-inducing agents were purchased from Sigma-Aldrich.
Cell differentiation was assessed morphologically and by CD11b cell surface antigen expression. For the morphological observation, cytospins were stained with May-Grü nwald-Giemsa (Merck), evaluated by light microscopy (Nikon E800, Japan), captured with a digital camera DMX1200, and recorded by Leika software. For reasons of simplicity, the morphologic phenotypes were classified into broad stages of differentiation: promyelocytes and myelocytes, metamyelocytes, and banded and segmented neutrophils. For immunophenotyping, 5 ϫ 10 5 cells were collected, washed, and incubated with monoclonal mouse antihuman PE-labeled anti-CD11b antibody for 30 min at 4°C. Mouse anti-IgG1 was used for isotope control. Fluorescence intensity was detected by FACScan flow cytometer (Becton Dickinson, Basel, Switzerland) and analyzed using FlowJo Software. Data were based on examination of at least 20,000 cells/sample.
In vitro differentiation of cord blood-derived CD34 ϩ progenitor cells
Cord blood samples were isolated from placentas acquired from mothers with normal, full-term deliveries at Scripps Memorial Hospital. CD34 ϩ progenitor cells were isolated with the MiniMACS separation unit (Miltenyi Biotec GmbH), as described by the manufacturer and expanded in IMDM supplemented with 10% FBS, 1% penicillin/streptomycin, 50 ng/mL stem cell factor, 50 ng/mL IL-3, and 10 ng/mL IL-6. After expansion, cells were further cultured with 10 ng/mL hrG-CSF for neutrophil or with 3000 U/mL hrM-CSF for monocytic differentiation. Cell differentiation was evaluated as described above.
Lentiviral vector cloning, lentivirus preparation, and transduction
The open reading frames of wild-type and kinase-inactive K52A mutant of human DAPK2 were amplified using the Expand High Fidelity PCR system (Roche Diagnostics, Rotkreuz, Switzerland) and the following primers: forward 5Ј-GGATCCGCCGCCACCATGGACTACAAGGACGACGATGACAAGATG-TTCCAGGCCTCAATGA-3Ј and reverse 5Ј-GAGGAGGAGCAGTACCTC-CTAACTCGAG-3Ј; as templates for the amplification of human wild-type and kinase-inactive DAPK2 cDNAs in elongation factor-1X(EF) mammalian vector (pEF-BOS), plasmids were used (kindly provided by Dr. Taro Kawai Research Institute for Microbial Diseases, Osaka University, Osaka, Japan). BamHI and XhoI sites were added to the amplification primers for subcloning as well as a KOZAK consensus sequence 5Ј of the ATG start signal for efficient expression in mammalian cells. The PCR products were cloned into the pCR-XLtopoisomerase (TOPO) vector (TOPO telomerase activity cloning kit, Invitrogen, Basel, Switzerland), and the recombinant clones were sequenced. The gel-purified BamHI/XhoI-digested fragments were subcloned further into the CGW lentiviral transfer vectors 5Ј of an internal ribosomal entry site-enhanced green fluorescent protein (EGFP) reporter (sequence upon request) by standard cloning techniques (RAPid DNA ligation kit, Roche Diagnostics). MISSION TM lentiviral clones expressing short hairpin RNAs (shRNAs), targeting DAPK2 (NM_014326.x-557, -675, and -1735) and a nontargeting shRNA control (SHC002) were purchased from Sigma-Aldrich. These vectors contain a puromycin, antibiotic-resistance gene for selection of transduced mammalian cells.
Lentivirus production and titer determination were done as described [27] . Briefly, the third-generation, self-inactivating glycoprotein of vesicular stomatitis virus (VSV-G)-pseudotyped virion particles were produced by transient cotransfection of the packaging plasmids pMD.G (VSV-G), pMDLg/p.RRE (gag and pol), and pRSV-Rev (Rev gene), as well as the lentiviral transfer vector.
Viral supernatant was harvested 48 h later, and viral titers were determined by infecting 293T cells. NB4 cells were transduced twice overnight in the presence of 8 g/mL polybrene using lentivirus at a multiplicity of infection of 10, thereafter washed and maintained as described above.
Real-time quantitative RT-PCR (RQ-PCR)
Total RNA was extracted using the RNeasy mini kit and the RNase-free DNase set, according to the manufacturer's protocol (Qiagen AG). Briefly, 1-2 g total RNA in 10 l was reverse-transcribed using random primers (Roche Diagnostics) and Moloney murine leukemia virus RT (Promega, Catalys AG, Wallisellen, Switzerland). PCR and fluorescence detection were performed using the ABI PRISM 7700 sequence detection system (Applied Biosystems, Rotkreuz, Switzerland) according to the manufacturer's protocol in a reaction volume of 25 l containing 1ϫ TaqMan Universal PCR master mix (Applied Biosystems) and 15-25 ng cDNA.
For quantification of DAPK2, lactoferrin (LF), G-CSF receptor (G-CSFR), and C/EBPε cDNA, 1ϫ Taqman gene expression assays, were used (Applied Biosystems, Assay ID Hs00204888_m1, Hs00158924_m1, Hs00167918_m1, and Hs00357657_m1, respectively). For the housekeeping gene porphobilinogen deaminase (PBGD), we used 5Ј-GGCAATGCGGCTGCAA-3Ј and 5Ј-GGGTACCCACGCGAATCAC-3Ј at 300 nM and 5Ј-FAM-CTCATCTTT-GGGCTGTTTTCTTCCGCCT-TAMRA-3Ј at 200 nM. All measurements were performed in duplicates, and the arithmetic mean of the comparative threshold cycle (Ct) values was used for calculations: Target gene mean Ct values were normalized to the respective housekeeping gene (PBGD) mean Ct values (internal reference gene, ⌬Ct) and then to the experimental control (⌬⌬Ct). Obtained values were exponentiated (2 -⌬⌬Ct ) to be expressed as n-fold changes in regulation compared with the experimental control (⌬⌬Ct method of relative quantification) [29] .
Protein extraction and Western blotting
Whole cell extracts were prepared using the nuclear extract kit (Active Motif, Rixensart, Belgium), and 10 -25 g protein was loaded on a 10% denaturing polyacrylamide gel. Blots were incubated with the primary antibodies in TBS 0.05% Tween-20/2.5% milk overnight at 4°C, incubated with secondary HRP-coupled antimouse or -rabbit antibody at 1:5-10,000 for 1 h at room temperature, and analyzed chemoluminescently using the ECL detection kit (Amersham, Freiburg, Germany). Used primary antibodies were anti-DAPK2 rabbit polyclonal antibody (psc2323, ProSci, Inc., Poway, CA, USA), 1:500, anti-EGFP rabbit polyclonal antibody (Molecular Probes, Basel Switzerland), and anti-␤-actin mouse mAb (Sigma-Aldrich), 1:10,000.
Freshly isolated granulocytes and monocytes were lysed as described elsewhere to prevent protein degradation from the leukocyte-proteases [30] . Briefly, freshly isolated cells (5ϫ10 6 ) were incubated at 99°C for 5 min, and then 5ϫ sample buffer (10% SDS, glycerol, Tris-HCl, 1 M, pH 6.8, H 2 O, bromophenol blue, and 20% ␤-ME) and DTT (final concentration 5 mM) were added, again incubated for 5 min at 99°C, and loaded on a SDS-PAGE gel. A prestained standard (Dual Color Standards, Bio-Rad, Hercules, CA, USA) was included in each run.
Statistical analysis
Analyses were performed using the Mann-Whitney rank sum or Kruskal-Wallis one-way test (SigmaStat 3.0). Graphs were done using the software SigmaPlot (8.0).
RESULTS
Disparate DAPK2 expression during mono-and granulocytic differentiation of leukemic cell lines DAPK2 mRNA was found to be up-regulated in an oligonucleotide microarray analysis designed to identify genes whose expression is regulated by ATRA-induced granulocytic differentiation. Our microarray analysis of Day 5 ATRA-treated NB4 cells demonstrated that DAPK2 levels were induced ninefold as compared with nontreated cells. A detailed description of the gene expression studies will be reported elsewhere. To confirm our microarray results, we used RQ-PCR to quantitatively evaluate DAPK2 expression during ATRA-mediated in vitro differentiation of NB4 leukemic cells. DAPK2 mRNA levels increased 110-fold 1 day after ATRA treatment and increased to 589-fold by Day 6 with respect to baseline levels. In contrast, an ATRA-resistant NB4 subline, NB4-R2, displayed only a minor DAPK2 increase of 27-and 34-fold on Days 1 and 6, respectively (Fig. 1A) . This increase of DAPK2 mRNA in NB4 was paralleled by an increase of DAPK2 protein levels (Fig. 1B) . Furthermore, ATRA induced a significant, dose-dependent increase of DAPK2 mRNA expression with sevenfold induction with 10 nM, 160-fold with 100 nM, and 514-fold with 1000 nM ATRA, as compared with the baseline levels (Fig. 1C) . The dose-response of ATRA-induced DAPK2 mRNA was paralleled by the expression of CD11b as measured by flow cytometry (data not shown).
To investigate further whether changes in levels of DAPK2 transcripts are specific to the neutrophil pathway and not just limited to NB4 cells, we took advantage of the U937 cell line as an alternative leukemic cell line differentiation model. Differentiation of U937 cells during 6 days with 1 M ATRA induced a similar pattern of DAPK2 mRNA increase (530-fold) as in NB4 cells. In contrast, DAPK2 expression during monocytic differentiation using 16 nM PMA was significantly less pronounced (Fig. 1D) . Monocytic differentiation was confirmed by flow cytometry analysis of CD11b surface expression and by morphology (data not shown).
Taken together, these results demonstrate that DAPK2 is associated with ATRA-induced granulocytic differentiation in selected hematopoietic cell lines.
DAPK2 expression in normal primary and leukemic myeloid cells DAPK2 has been shown previously to be highly expressed in heart, lung, skeletal muscle, colon, breast, spleen, and leukocytes [2, 3] ; however, expression in various hematopoietic cell lineages has not been analyzed. As our findings from cell-line differentiation experiments suggest an involvement of DAPK2 in the myeloid maturation process, it is necessary to determine whether similar patterns of DAPK2 transcript and protein expression changes occur in primary hematopoietic cells. DAPK2 mRNA expression levels were measured in freshly isolated cord blood CD34 ϩ progenitor cells (CD34 ϩ ; nϭ6), granulocytes (G; nϭ9), and cultured macrophages derived from peripheral blood (M; nϭ8; Fig. 2A, left panel) . The results are presented relative to the values from the PBGD housekeeping gene. Human peripheral blood granulocytes showed a significantly higher expression of DAPK2 mRNA (median 119.4, range 14.9 -207.9) than cultured macrophages (median 0.023, range 0.004 -0.031, PϽ0.001) or human cord blood-derived CD34 ϩ progenitor cells (median 0.024, range 0.011-0.049, PϽ0.001; Fig. 2A, left panel) . This difference in DAPK2 expression was also reflected at the protein level. DAPK2 protein was highly expressed in granulocytes (G1 and G2) and was absent in monocyte extracts (M1 and M2) as shown by Western blotting (Fig. 2B) .
To study DAPK2 expression in malignant cells, we first evaluated various myeloid and solid cancer cell lines ( Table  1) . DAPK2 mRNA expression was low in most cell lines ϩ cord blood progenitor cells (median 0.024, range 0.011-0.049, PϽ0.091). DAPK2 levels were significantly higher, however, in CML-CP samples (median 13.2, range 3.8 -348.5, nϭ9, PϽ0.001) and in granulocytes (median 119.4, range 14.9 -207.9, PϽ0.001; Fig. 2A, right panel) . DAPK2 levels in granulocytes were significantly higher than in any other cells tested (PϽ0.001). A more detailed analysis of AML subtypes according to the FAB classification and cytogenetic subtypes revealed no significant differences in DAPK2 mRNA expression among the different subtypes (Kruskal-Wallis test, Pϭ0.720; Fig. 2C ).
In summary, our results obtained from hematopoietic cell lines and primary cells suggest that DAPK2 expression is abundant in cells differentiated toward granulocytes (as shown for primary granulocytes and CML-CP) and low in undifferentiated, normal and leukemic hematopoietic cells (as shown for cord blood CD34 ϩ progenitor cells and AML blasts) and in monocytes/macrophages. DAPK2 mRNA expression during myeloid differentiation of cord blood CD34 ϩ progenitor cells
To further confirm the distinct DAPK2 levels in granulocytes versus macrophages, we isolated CD34 ϩ progenitor cells from cord blood samples obtained from two healthy donors. CD34 ϩ cells were differentiated in vitro to neutrophils using hrG-CSF or to monocytes/macrophages using hrM-CSF. During neutrophil differentiation, DAPK2 mRNA levels increased from 1.4-to 3.4-fold at Day 6 and from 9.4-to 13.5-fold at Day 18 (Fig.  3A) , and the majority of the cells showed a granulocytic phenotype (Fig. 3B) . However, CD34 ϩ cells, differentiated to monocytes/macrophages using hrM-CSF, displayed little change in DAPK2 mRNA expression at Day 24. Moreover, when CD14 ϩ monocytes isolated from two healthy donors were induced to differentiate to macrophages using hrM-CSF, DAPK2 mRNA expression was reduced rather than increased (Fig. 3C ). These data demonstrate that DAPK2 is up-regulated exclusively during granulocytic but not during monocytic maturation.
DAPK2 expression enhances, whereas DAPK2 knockdown dampens, maturation of ATRAinduced NB4 cells toward granulocytes
Given the association of DAPK2 with neutrophil differentiation, we next asked whether expression of exogenous, wild-type DAPK2 enhances neutrophil differentiation. To accomplish our goals, a lentiviral vector expression system was used to ectopically and stably express the DAPK2 genes. Expression of DAPK2 gene cassette and EGFP from the same vector using an internal ribosomal entry site ensured that cells expressing DAPK2 could be identified by virtue of EGFP expression. One week after vector transduction of NB4 cells with wild-type DAPK2 (DAPK2.WT) or kinase-inactive DAPK2 K52A mutant (DAPK2.K52A), Ն90% of the cells were GFP-positive. NB4 cells transduced with an empty DAPK2 gene cassette vector expressing only EGFP served as a negative control. All three transduced cell lines could be maintained in culture over several weeks without apparent changes in the amount or the signal intensity of EGFP. To verify expression of the different DAPK2 transgenes, Western blot analysis was performed on transduced cell lines. Wild-type and kinase-inactive DAPK2 proteins were found to be expressed in cells transfected with the various DAPK2 vectors, but cells transduced with empty control vector remained negative (Fig. 4A, left panel) . Induction of endogenous DAPK2 was observed in the control cells upon 4 days of ATRA treatment (Fig. 4A, right panel) .
No obvious cellular markers of myeloid maturation were seen induced upon expression of wild-type DAPK2; however, upon treatment of transduced cells with 1 M ATRA, differentiation was enhanced when compared with the controls. Fig. 4B ). In addition, we measured mRNA levels of three genes, LF, G-CSFR, and C/EBPε, all known to be induced upon ATRA treatment. The NB4 cells expressing the control vector showed a 3600-, 15-, and 14-fold increase of LF, G-CSFR, and C/EBPε, respectively, from Days 0 to 6 of ATRA treatment (Fig. 4C) . Exogenous expression of wild-type DAPK2 upon ATRA treatment additionally increased mRNA levels of these genes. During 4/6 days of treatment with 1 M ATRA in cells expressing wild-type, DAPK2 LF mRNA expression was significantly increased 7-/9.6-fold, G-CSFR 1.4-/2-fold, and C/EBPε 1.3-/2-fold, as compared with the cells containing the control vector (Fig. 4D , Mann-Whitney Rank Sum test, PϽ0.05). The cells expressing the control vector or kinase-inactive DAPK2 K52A did not demonstrate increased levels of the granulocyte maturation marker program genes as compared with the control cells. The enhanced differentiation effect of wild-type DAPK2 expression was also evident morphologically after 6 days of treatment with 1 M ATRA. NB4 DAPK2.WT cells displayed a significantly smaller fraction of promyelocytes/myelocytes: 33.5% compared with 50% in cells with the control vector and 69% in DAPK2.K52A-containing cells. Moreover, a significantly greater fraction of mature neutrophils was present in cells expressing ectopic DAPK2, 37%, as compared with cells expressing the control vector, 20%, or cells containing DAPK2.K52A, 7% (Fig. 4E) . It is interesting that neither increased apoptosis nor cell cycle changes were observed in any of the cells bearing the three different vectors during 4 days of ATRA treatment, as assessed by 4Ј,6-diamidino-2-phenylindole (DAPI) or propidium iodide (PI)-stained nuclei (Supplemental Fig. 1) .
To further probe the function of DAPK2 in neutrophil differentiation, we used shRNA to DAPK2 message to knockdown DAPK2 in NB4 cells and investigated the effects on ATRAinduced differentiation. Lentiviral vectors expressing three different shRNAs targeting different regions of the DAPK2 mRNA (Clones 557, 675, and 1735) and a nontargeting ShRNA (SHC) were used to transduce NB4 cells. Expression of a puromycin-resistance gene from the same delivery vector allowed for puromycin selection of transduced cells. DAPK2 knockdown in puromycin-selected cell populations was confirmed by RQ-PCR. Upon ATRA treatment, all three DAPK2 knockdown cells displayed significantly lower CD11b surface expression as compared with the nontargeting, shRNA-expressing control cells (Fig. 4F) . After 4 days of ATRA treatment, DAPK2 was decreased 70 -80% in cells expressing the DAPK2 shRNAs. Assessment of the myeloid differentiation markers LF,G-CSFR, and C/EBPε showed significantly lower levels expressed in DAPK2 knockdown as compared with the control cells (Supplemental Fig. 2) .
Taken together, our results demonstrate a functional role for DAPK2 in ATRA-induced, granulocytic maturation.
DAPK2 expression in NB4 cells can be restored by demethylating therapy
In many cancers, low expression of DAPK1, the closest homologue of DAPK2, has been shown to be caused by promoter methylation [9] . Furthermore, treatment of DAPK1-negative cell lines with demethylating agents, such as 5Ј-aza-2Јdeoxy-cytidine (5Ј-AZA-dC), restored DAPK1 expression [31] . To test whether low or absent DAPK2 expression in leukemic NB4 cells may be a result of promoter methylation, we treated these cells with 5Ј-AZA-dC. It is interesting that treatment of NB4 cells with increasing amounts of 5Ј-AZA-dC during 2 days showed a dose-and time-dependent increase of DAPK2 expression (Fig. 5) . These findings, together with the low DAPK2 expression in primary leukemias, suggest that low DAPK2 expression is, at least partially, a result of promoter silencing.
DISCUSSION
We report for the first time that DAPK2 may play a role in human granulocytic maturation. The arguments supporting this claim and demonstrated in our experiments are: distinct granulocyte-pathway-specific DAPK2 up-regulation in vitro and in vivo; significant differences in DAPK2 expression between human immature CD34 ϩ hematopoietic progenitor cells versus mature granulocytes; low expression of DAPK2 in AML but high expression in CML-CP; stable cell line transfection experiments providing evidence for the role of DAPK2 as an enhancer of ATRA-induced granulocytic differentiation; and DAPK2 knockdown attenuates terminal neutrophil maturation. DAPK2 belongs to the CaM-dependent serine/threonine kinase subfamily of death-associated protein kinases, previously shown to induce apoptosis when overexpressed in nonhematopoietic cell lines [2, 3] . A number of preliminary observations reported in the literature have suggested a critical link between various CaM kinases and myeloid differentiation. CaM kinase subtypes (CaMKI, CaMKIV, and particularly, CaMKK␣) have been shown to be regulated differentially during ATRA-and hrG-CSF-dependent neutrophil maturation [22] . Furthermore, Verploegen et al. [23] recently identified a CKLiK with granulocyte-restricted expression and function. In the hematopoietic system, increased DAPK2 expression was reported during the differentiation of erythroid progenitor cells toward latestage erythrocytes, most likely via Epo-receptor signaling [32] . Our results are consistent with these previous observations and suggest further that DAPK2 may be critical for terminal differentiation of selected hematopoietic lineages.
It is interesting that the DAPK2 gene maps to chromosome 15q22, a region known to be altered in some hematopoietic malignancies [33] . In addition, DAPK1, which shares high kinase domain homology with DAPK2, has previously been shown to be silenced in many hematological disorders [9, 10] , among them AML [11] , acute lymphoblastic leukemia [12, 13] , myelodysplastic syndrome [14] , non-Hodgkin's lymphoma [15, 16] , and myeloma [17] , through promoter hypermethylation. Furthermore, DAPK1 was reported to be overexpressed in CD34 ϩ /CD38 -progenitor cells from patients with AML as compared with CD34 ϩ /CD38 -cells from healthy donors, thereby suggesting a contribution of DAPK1 to the pathogenesis of early leukemic (stem) cell characteristics [24] . To elucidate a possible implication of DAPK2 in leukemogenesis, we first compared DAPK2 expression in myeloid and nonmyeloid malignant cells. We found that myeloid cell lines, particularly, cells blocked at the promyelocyte stage, showed weak DAPK2 mRNA expression compared with the solid tumor cell lines. Furthermore, RQ-PCR examination of 100 primary AML and nine CML-CP samples revealed that blast cells from AML show similar expression levels as immature CD34 ϩ cord blood progenitor cells but significantly lower than CML-CP and granulocytes.
As AML blasts represent an immature hematopoietic phenotype, and cells from CML-CP patients are a mixture of fully differentiated (granulocytes) and immature blood cells, our DAPK2 expression results in normal myeloid and leukemic cells suggest that DAPK2 expression levels correlate tightly with the stage of cell differentiation toward granulocytic phenotype. It is possible that the low DAPK2 expression observed in AML blasts may contribute to the differentiation block seen in AML. The mechanism leading to suppression of DAPK2 expression is unclear to date. Analogous to DAPK1 silencing, it is conceivable that it might be mediated through epigenetic silencing. Our data showing a time-and dose-dependent increase of DAPK2 mRNA upon treatment with the demethylating agent 5Ј-AZA-dC further support this possibility. However, further studies are needed to confirm that DAPK2 promoter methylation is indeed the major silencing mechanism for DAPK2 in leukemia in light of our findings demonstrating a lower DAPK2 increase upon 5Ј-AZA-dC as compared with ATRA treatment.
Stable, lentiviral vector-mediated expression of wild-type DAPK2 enhanced ATRA-induced granulocytic differentiation Fig. 5 . Treatment of NB4 cells with demethylating agent 5Ј-AZA-dC restores DAPK2 expression. NB4 cells were cultured during 2 days in the presence of increasing concentrations of 5Ј-AZA-dC as indicated, and relative changes in DAPK2 transcripts were determined using RQ-PCR at time-points indicated. Relative DAPK2 mRNA levels were normalized to PBGD expression, and results are expressed as n-fold regulation compared with Day 0. Data are given as mean Ϯ SD of three independent experiments. of NB4 cells, as shown by morphology and CD11b expression. Furthermore, up-regulation of mRNA levels of key regulator genes for terminal differentiation, such as C/EBPε [20, 34, 35] , the G-CSFR [36, 37] , and the secondary granule protein LF [38 -40] , were also enhanced. A kinase-inactive DAPK2 K52A mutant showed no such effects, thus demonstrating that functional DAPK2 is required. In line with these results, we further show that shRNA-mediated knockdown of DAPK2 expression attenuates terminal granulocytic differentiation. Therefore, our findings underscore a role for the involvement of DAPK2 in pathways responsible for terminal maturation of neutrophils and of genes important for neutrophil effector functions. Although DAPK2 may activate important downstream effectors of hematopoietic differentiation and neutrophil function, as of yet, no DAPK2 targets have been described so far apart from the myosin light chain gene [2, 3] .
It is at present unclear which signaling pathway(s) require DAPK2 to mediate the biological effects seen in our studies of hematopoietic cells. A recently proposed role for DAPK2 in autophagy or Type II cell death in nonhematopoietic cells [41] may provide insight into DAPK2 function in myeloid cells. Autophagy is a cellular process characterized by the sequestration of portions of the cytoplasm or cytoplasmic organelles into double membrane-bounded vesicles, autophagosomes, which subsequently fuse with the lysosomal system of the same cells, resulting in degradation of the vesicle contents. This process is in principle a cytoplasmic homeostasis pathway, eliminating damaged organelles and promoting turnover of stable macromolecules to support cellular anabolic needs, particularly during starvation. It is interesting that autophagy has also been implicated in cellular architecture changes occurring in differentiation and development, in malignant transformation, and recently, in innate and adaptive immunity [42] [43] [44] . It is presently unclear which role, if any, autophagy plays in granulocyte differentiation and/or function or leukemogenesis; however, the observed participation of DAPK2 in granulocytic maturation warrants further investigation.
In conclusion, our findings strongly implicate a role for DAPK2 in neutrophil maturation and in regulating terminal differentiation programs. Moreover, the significantly lower DAPK2 mRNA levels in AML suggest that alterations of DAPK2 expression may predispose for leukemogenesis.
